Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use LISRAYA safely and effectively. See full prescribing information for LISRAYA. LISRAYA (brepocitinib) tablets, for oral useInitial U.S. Approval: 2026
Medication labelWhy this: Advisory · dailymed-prescription
LISRAYA is indicated for the treatment of dermatomyositis in adult patients. Limitations of Use LISRAYA is not recommended for use in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.
- generic_name
- brepocitinib
- product_names
- brepocitinib
- ndc
- 87211-030, 87211-030-30
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en